With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company ...

Vertex Pharmaceuticals got a healthy boost on Tuesday, with shares climbing nearly 3% thanks to a double dose of analyst ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals earned well-deserved kudos after Dr. Paul Negulescu snagged the 2025 Canada Gairdner International ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 2.10% to $482.30 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% ...

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

President Donald Trump assured Republicans that his “Liberation Day” tariffs will have a positive impact, teasing coming levies on pharmaceuticals as well. Speaking at the National Republican ...

Prime Minister Anthony Albanese has again vowed to never negotiate on the Pharmaceutical Benefits Scheme in discussions with the United States on tariffs. Meanwhile, Peter Dutton has officially ...